

Biosimilars indicated in the treatment of autoimmune disease  
(Marketed and in clinical development as of January 2014.  
Updated 22<sup>nd</sup> Jan)



Innovator product	Biosimilar	Developer(s)	Development status
<b>Remicade® (Infliximab:J&amp;J)</b>			
Marketed	Remisma® Inflectra™ Flammegis®	Celltrion Marketed as Inflectra® by Hospira and Flammegis® by Egis Pharmaceuticals in some CIS countries, Remsima® in Korea and other countries	Approved Korea Approved some CIS countries Approved EU Approved Colombia Approved Canada In review Japan
In development	BOW-015 GS-071 NI-071 R-TPR-015 SB2 PF-06438179	EPIRUS Biopharma Schnell Biopharma Nichi-Iko (Japan) Reliance Life Sciences Samsung Bioepis Pfizer	Phase III (RA) Phase III (Japan: RA) Phase I (Korea: RA) Phase III ( RA) Phase I/II (RA) Phase I (Pk)
<b>Humira® (Adalimumab: AbbVie)</b>			
In development	ABP 501 GP2017 BI 695501 PF-06410293 KB327 Adalimumab biosimilar	Amgen Sandoz Boehringer Ingelheim Pfizer Fujifilm Kyowa Kirin Biologics Zydus Cadila	Phase III (RA) Phase III (PTP) Phase I (Pk) Phase I (Pk) Phase I (Pk) Phase I/II (RA)
Biosimilars indicated in the treatment of autoimmune disease in clinical development as of January 2014. RA= rheumatoid arthritis; PTP= chronic plaque type psoriasis; Pk= pharmacokinetic equivalence study in healthy subjects			

Biosimilars indicated in the treatment of autoimmune disease  
(Marketed and in clinical development as of January 2014.  
Updated 22<sup>nd</sup> Jan)



Innovator product	Biosimilar	Developer(s)	Development status
<b>Enbrel® (Etanercept: Amgen)</b>			
Marketed	Etacept	Cipla	Approved India
	Etanar® (Colombia)/ Yisaipu (China)	Shanghai CP Goujian Pharmaceutical Co	Approved Colombia and China
In development	GP2015	Sandoz	Phase III (PTP)
	Hanwha Chemical	HD203	Phase III
	SB4	Samsung Bioepsis	Phase III (RA)
	TuNex/ENIA11	Mycenax Biotech	Phase III (RA)
	DWP422	Daewoong Pharmaceutical Co	Phase I (Pk)
	LBEC0101	LG Life Sciences	Phase I (Pk)
	CHS-0214	Coherus Biosciences)	Phase I (Pk)
<b>Rituxan®/MabThera® (Rituximab: Roche)</b>			
Marketed	Reditux	Dr Reddy's Laboratories	Approved India, Chile, Bolivia and Peru
	Mabtas®	Intas Pharmaceuticals	Approved India
	Kikuzubam®	Probiomed	Approved Mexico, Bolivia and Chile
In development	BI 695500	Boehringer Ingelheim	Phase III (RA)
	BCD-020	Biocad	Phase III (RA)
	PF-05280586	Pfizer	Phase I/II (RA)
	MK8808	MSD	Phase I (RA)
Biosimilars indicated in the treatment of autoimmune disease in clinical development as of January 2014. RA= rheumatoid arthritis; PTP= chronic plaque type psoriasis; Pk= pharmacokinetic equivalence study in healthy subjects			